Compare Global X MSCI Argentina ETF (ARGT) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X MSCI Argentina ETF vs AstraZeneca plc — how do they compare? Global X MSCI Argentina ETF trades at $91.29, while AstraZeneca plc trades at $158.39 (market cap $248.14B). The key difference: AstraZeneca plc pays a 2.01% dividend while Global X MSCI Argentina ETF pays none, and Global X MSCI Argentina ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| ARGT | AZN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $209.48 |
52-Week Low | $67.55 | $147.06 |
Market Cap | — | $248.14B |
Enterprise Value | — | $275.41B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARGT is trading at $91.95, down 1.58% today amid bearish technical signals. The ETF shows neutral momentum oscillators but bearish moving averages, with key support at $92. Recent Seeking Alpha analysis (June 18, 2026) highlights Argentina's economic reforms creating potential for 28% upside, though financial ratios remain undisclosed. The fund's concentration in MercadoLibre presents both opportunity and risk as Argentina's monetary backdrop improves.
The outlook suggests cautious optimism with reform progress driving potential re-rating, though technical weakness and single-country concentration require careful risk management. Near-term performance hinges on Argentina's economic stabilization and institutional investor confidence, with Stanley Druckenmiller's recent position (Q1 2026) indicating sophisticated investor interest.
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X MSCI Argentina ETF
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
